UBS Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $214
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
UBS analyst Ashwani Verma maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and lowers the price target from $231 to $214.
UBS analyst Ashwani Verma maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and lowers the price target from $231 to $214.